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ABSTRACT. Trumenba (bivalent rLP2086) is a vaccine licensed for the prevention of
meningococcal meningitis disease caused by Neisseria meningitidis serogroup B (NmB) in
individuals 10–25 years of age in the USA. The vaccine is composed of two factor H binding
protein (fHbp) variants that were recombinantly expressed in Escherichia coli as native
lipoproteins: rLP2086-A05 and rLP2086-B01. The vaccine was shown to induce potent
bactericidal antibodies against a broad range of NmB isolates expressing fHbp that were
different in sequence from the fHbp vaccine antigens. Here, we describe the characterization
of the vaccine antigens including the elucidation of their structure which is characterized by
two distinct motifs, the polypeptide domain and the N-terminal lipid moiety. In the vaccine
formulation, the lipoproteins self-associate to form micelles driven by the hydrophobicity of
the lipids and limited by the size of the folded polypeptides. The micelles help to increase the
structural stability of the lipoproteins in the absence of bacterial cell walls. Analysis of the
lipoproteins in Toll-like receptor (TLR) activation assays revealed their TLR2 agonist
activity. This activity was lost with removal of the O-linked fatty acids, similar to removal of
all lipids, demonstrating that this moiety plays an adjuvant role in immune activation. The
thorough understanding of the structure and function of each moiety of the lipoproteins, as
well as their relationship, lays the foundation for identifying critical parameters to guide
vaccine development and manufacture.
KEY WORDS: bivalent rLP2086; factor H binding protein; meningococcal meningitis B vaccine;
Neisseria meningitidis serogroup B; self-adjuvanting vaccine.
INTRODUCTION
Neisseria meningitidis, also called meningococcus (Men),
is a human commensal Gram-negative bacterium that can
cause severe disease with substantial mortality and morbid-
ity. Survivors can suffer from permanent neurological
sequelae and limb loss. N. meningitidis is categorized by its
capsular polysaccharides into 12 serogroups, of which six
cause the majority of disease (1). Four of the serogroups (A,
C, Y, W) can be controlled with capsular polysaccharide-
based vaccines. A capsular polysaccharide-based vaccine
approach was not feasible for protection against
N. meningitidis serogroup B (NmB) (2) due to the low
immunogenicity of the serogroup B capsular polysaccharide
(3), which is similar to structures found on human neuronal
cells (4). In regions where the A, C, Y, W vaccines are
routinely used, endemic NmB disease is often the most
common cause of meningococcal disease in infants, children,
and young adults (1). NmB also causes outbreaks in various
settings and regions. To control these outbreaks, vaccines
based on the highly variable porin A protein were used, but
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these vaccines were not broadly effective against other
invasive NmB strains (5,6).
Recently, two vaccines were developed and licensed for
the prevention of NmB disease: Trumenba (bivalent
rLP2086) and Bexsero (4CMenB). While the vaccines have
different compositions, they each include factor H binding
protein (fHbp) components (7). fHbp is a surface-expressed
lipoprotein capable of inducing serum bactericidal antibodies
that can be assessed in serum bactericidal assays that utilize
human complement (hSBA). Anti-fHbp antibodies were
found in convalescent sera from subjects that contracted
meningococcal disease, supporting the expression of fHbps on
meningococcal bacteria and their in vivo immunogenicity (8).
fHbp is also an important virulence factor expressed by
N. meningitidis to evade innate immune defenses by specif-
ically binding to complement factor H (fH) (9). It was
suggested that anti-fHbp antibodies can elicit protection by
two mechanisms: direct complement-mediated killing of the
bacterium and blocking fH binding to the bacteria to increase
the susceptibility of the bacterium to killing by the alternative
complement pathway (7,10).
The amino acid sequences of fHbps segregate into two
immunologically distinct subfamilies, subfamily A and sub-
family B (11). Bexsero contains one recombinant subfamily B
protein (v1.1/B24) that is non-lipidated and expressed as a
fusion protein (12). B24 is found in 43.8% and 16.7% of
invasive NmB strains in the USA and Europe, respectively
(13). Thus, additional non-fHbp components were included in
Bexsero to extend the coverage of the vaccine to other strains
(14). Trumenba contains two lipidated fHbp variants, one
from subfamily A (variant A05) and one from subfamily B
(variant B01). Early research by Pﬁzer scientists established
that the lipidated version of fHbp elicited broader hSBA
responses compared to its non-lipidated form (11).
Bacterial lipoproteins consist of a polypeptide and an N-
terminal lipid moiety and are found anchored to the cell
surface of bacteria. These lipids commonly contain two fatty
acids of various structures acyl-linked to two hydroxyl groups
(O-acyl or O-linked fatty acid) of a glycerol, which is
thioether-linked to the N-terminal cysteine of the mature
polypeptide, resulting in a di-O-acylated lipid. An additional
fatty acid is acyl-linked to the α-amine of the N-terminal
cysteine (N-acyl or N-linked fatty acid), giving rise to a tri-
acylated lipoprotein. A schematic structure of the tri-acylated
lipid moiety, containing three C16:0 (16-carbon chain with all
saturated bonds) fatty acids, is shown in Fig. 1. Anchoring of
the lipid motif in the outer membrane of the bacteria exposes
the polypeptide to the bacterial cell surface, thus making it
accessible to bactericidal antibodies directed to the protein
(15).
In this work, we report the detailed characterization of
the structures of rLP2086-A05 and rLP2086-B01, as well as
the structure–function relationships, using multiple biochem-
ical and biophysical techniques.
MATERIALS AND METHODS
Materials
Trumenba is composed of two fHbps. The subfamily A
protein, rLP2086-A05, and the subfamily B protein, rLP2086-
B01, were recombinantly expressed in E. coli suspension cell
cultures. The puriﬁed bulk solutions of individual lipopro-
teins, and the vaccine product composed of equal amounts of
both lipoproteins, were supplied by Pﬁzer’s manufacturing
facility. The non-lipidated version of rLP2086-B01, rP2086-
B01, was produced as described previously (16). All reagents
used were of the highest purity commercially available, and




Gas chromatography–mass spectrometry (GC/MS) was
used to analyze the composition of fatty acids released from
rLP2086-A05 and rLP2086-B01 via acid hydrolysis and
transesteriﬁcation to picolinyl esters. The details are de-
scribed in Supplemental 1.
Peptide Mapping by Liquid Chromatography/Mass
Spectrometry
Non-reduced proteolytic mapping of rLP2086-A05 and
rLP2086-B01 with lysyl endoproteinase (Lys-C) was used to
characterize the primary sequence and posttranslational
modiﬁcations of the polypeptide domain, as well as
conﬁrming the fatty acid compositions of the lipid moiety.
The details are described in Supplemental 1.
Mass of Intact Lipoproteins by LC/MS
Accurate molecular masses were determined for the
intact rLP2086-A05 and rLP2086-B01 by a Waters Acquity
UHPLC/UV system interfaced to an ultrahigh-resolution
(UHR) Bruker Daltonics maXis electrospray ionization
quadrupole time-of-ﬂight (ESI-QTOF) mass spectrometer.
The samples were analyzed by injecting approximately 6 μg
onto a Waters BEH C4 column (2.1 × 100 mm, 1.7 μm) at a
temperature of 60°C and eluted at a ﬂow rate of 0.2 mL/min
with a gradient from 20% to 90% of mobile phase B (0.1%
TFA in acetonitrile); mobile phase Awas 0.1% TFA in water.
The elution proﬁles were monitored with UV detection at
215 nm. The observed multiply charged ion envelope for each
lipidated NmB rLP2086 component was deconvoluted and
Fig. 1. Schematic structure of a bacterial lipoprotein. The N-terminal
S-glycerylcysteine is tri-acylated with three palmitoyl fatty acids
(C16:0). R1 is the N-linked fatty acid; R2 and R3 are the O-linked
fatty acids
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de-isotoped with the Bruker Daltonics maximum entropy and
SNAP algorithms, respectively, to generate neutral, monoiso-
topic masses.
Circular Dichroism and Differential Scanning Calorimetry
Far-UV circular dichroism (CD) in the 180- to 250-nm
range and near-UV CD in the 250- to 350-nm range were
used to characterize the secondary and tertiary structures of
rLP2086 lipoproteins, respectively. Differential scanning
calorimetry (DSC) was used to compare their thermal
stability. The details are described in Supplemental 1.
Size Exclusion Chromatography and Multi-angle Light
Scattering
Isocratic fractionation by size exclusion high-
performance liquid chromatography (SE-HPLC) was per-
formed using Waters Alliance 2695 Separations Module and
Tosoh Bioscience TSK G4000SWXL column (7.8 mm ×
30 cm, 8 μm). Other details are described in Supplemental 1.
Raleigh light scattering theory allows determination of
the weight average molar mass in a sample if the concentra-
tion is known. Therefore, light scattering signals in-line with
UV detection provided molar mass information for each SE-
HPLC fraction. Wyatt Technology DAWN HELEOS II light
scattering detector was used. The data were collected and
analyzed using the manufacturer-provided software ASTRA
v5.3.4.20.
Analytical Ultracentrifugation
Analytical ultracentrifugation sedimentation velocity
experiments were performed on a Beckman XL-I analyt-
ical ultracentrifuge to characterize the size distribution of
rLP2086s in various solution conditions. Samples were
loaded into double-sector (1.2-cm path length) carbon-
Epon centerpieces in an An-60 Ti rotor. Scans were
recorded by UV absorbance at a wavelength of 282 nm
with a spacing of 0.006 cm in the continuous mode and at
20°C using a rotor speed of 42,000 rpm (or as indicated in
the ﬁgure legend). The sedimentation coefﬁcient distribu-
tions, c(s), were obtained using the program SEDFTT
(17).
Lipase De-esterification
Thermomyces lanuginosus lipase, which is highly spe-
ciﬁc in hydrolyzing ester-bound (O-linked) fatty acids with
no amidase activity (18), was purchased from Sigma
(Lipase, L0777) and used to produce de-esteriﬁed N-acyl
rLP2086-A05. The protease impurities were removed using
anion exchange chromatography (Q Sepharose) and hydro-
phobic interaction chromatography (Phenyl Sepharose)
prior to the lipid de-esteriﬁcation treatment to protect the
polypeptides of the lipoprotein. Other details are described
in Supplemental 1.
In Vitro Toll-Like Receptor Assay Using hTLR2-Transfected
Cells
Commercial HEK-Blue™ hTLR2 cells (InvivoGen
#hkb-htlr2) are produced by co-transfection of the human
Toll-like receptor 2 (TLR2), CD14 co-receptor, and SEAP
(secreted embryonic alkaline phosphatase) genes into
HEK293 cells. The cells also express endogenous levels of
TLR1, TLR3, TLR5, and TLR6 (http://www.invivogen.com/
PDF/HEK_Blue_hTLR2_TDS.pdf). Bacterial lipoproteins
and lipopeptides are reported to interact only with TLR2
(can be complexed with TLR1 or TLR6), but not with TLR3
and TLR5. Stimulation of the TLR2-transfected cells by TLR
ligands can induce the production of SEAP. The phosphatase
activity of SEAP, which is proportional to the level of
stimulation, can be quantitated using colorimetric assays.
HEK293 hTLR2 cells were incubated individually with intact
(tri-acylated) NmB rLP2086-A05 vaccine drug substance or
drug product, lipase de-esteriﬁed N-acyl (mono-acylated)
NmB rLP2086-A05, Pam3CSK4 (a commercial TLR2/TLR1
agonis t s tandard; InvivoGen #t lr l -pms or EMC
microcollections #L2000), or phosphate-buffered saline
(PBS; Life Technologies #10010-023) for 20–22 h at 37°C.
Each sample was made minimally in duplicate. The cell
supernatant was diluted into QUANTI-Blue detection me-
dium (InvivoGen #rep-qb1) and incubated at 37°C for 1–3 h
prior to measuring the absorbance at 620–655 nm for SEAP
phosphatase activity. For certain experiments, the cells were
pre-incubated with an anti-TLR2 neutralizing monoclonal
antibody (InvivoGen #maba2-htlr2) to discern the role of
TLR2 in the resulting response.
Homology Modeling of rLP2086-A05
A homology model of rLP2086-A05 was built using the
nuclear magnetic resonance (NMR) structure of rLP2086-B01
as a template (PDB entry: 2KDY). The details are described
in Supplemental 1.
RESULTS
Primary Structure and Posttranslational Modifications
Identification and Characterization of Fatty Acids by GC/MS
The E. coli-expressed rLP2086-A05 and rLP2086-B01
are inherently heterogeneous due to expected variations in
fatty acid compositions of the lipids, possible posttranslational
modiﬁcations to amino acids in the polypeptide region, or
both. Separate analyses of the fatty acid compositions by GC/
MS and polypeptide structures by liquid chromatography–
mass spectrometry (LC/MS) provided the basis for complete
characterization of the primary structure of both recombinant
lipoproteins.
The GC proﬁles of the picolinyl esters of fatty acids
hydrolyzed from the two lipoproteins are shown in Fig. 2. The
identiﬁcations of fatty acids were based on mass values and
the fragmentation patterns. The complete fragmentation
achieved for each chromatographically resolved fatty acid
also allowed localization of the unsaturated or cyclic groups
in the fatty acids. Exemplary MS spectra for C16:0, C16:1,
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and C17:cyclo are shown in Supplemental 2 Fig. S-1. More
details for the GC/MS-based structural assignment are
described in Supplemental 1.
Despite the structural heterogeneity of the fatty acids in
rLP2086-A05 and rLP2086-B01 as assessed by GC/MS, the
two lipoproteins exhibited highly similar fatty acid composi-
tions. The three major components—C16:0, C16:1, and
C18:1—accounted for >90% of the total fatty acids. The fatty
acids at minor and trace levels are C14:0, C15:0, C17:cyclo,
and C19:cyclo. These results were conﬁrmed by the LC/MS
analyses, as described below. It is noted that no fatty acid
shorter than C14 was observed, which has profound implica-
tion to the functionality of the lipid moiety.
Amino Acid Sequence Confirmation and N-Terminal Lipid
Structure Elucidation by Peptide Mapping LC/MS
NmB rLP2086-A05 and rLP2086-B01 are predicted from
the DNA sequences to consist of 258 and 261 amino acids,
respectively. The two polypeptides share only ∼69% se-
quence identity. Non-reduced Lys-C peptide mapping via LC/
MS was carried out, as described in BMethods,^ to analyze the
amino acid sequence and posttranslational modiﬁcations, as
well as to elucidate the compositions of the tri-acyl N-
terminal lipid moiety. There are 27 and 22 Lys-C peptides in
rLP2086-A05 and rLP2086-B01, respectively, predicted from
the respective amino acid sequence. The N-terminal peptides
are predicted to contain 28 and 33 amino acids, respectively,
each covalently linked to a tri-acylated lipid moiety.
All predicted Lys-C digested amino acid peptides of
rLP2086-A05 (L2–L26) and rLP2086-B01 (L2–L21) were
identiﬁed by mass spectrometry in the peptide region
(<30 min) of the reversed-phase ultrahigh-performance
liquid chromatography (RP-UHPLC) peptide map UV
proﬁle, as shown in Fig. 3 (L27 of rLP2086-A05 and L22
of rLP2086-B01 are single amino acid residues, Q, at the
C-termini, which were not detected). The relative mass
errors between the predicted and the observed mass values
for all peptides were less than 5 ppm. The mass values of
all predicted and detected peptides, including the modiﬁed
peptides, are provided in Supplemental 3 (Tables S-I and
S-II).
Due to the hydrophobic nature of the lipids, the N-
terminal lipopeptides eluted late in a distinct region (>46 min;
Fig. 3), which permitted separate analyses of the N-terminal
lipopeptides, L1, from all other peptides. This RP-UHPLC
method was also capable of resolving most of the lipid
isoforms of the N-terminal lipopeptides, as shown in the
insets of Fig. 3, which facilitated the elucidation of the fatty
acid compositions for the tri-acylated lipid moiety based on
the fatty acid structures and their relative abundance attained
by GC/MS. The observed monoisotopic molecular masses for
Fig. 2. GC proﬁles of fatty acid picolinyl esters derived from NmB rLP2086-A05 (a) and
rLP2086-B01 (b) lipoproteins. C17:0 IS denotes C17:0 fatty acid that was used as an
internal standard. Asterisk denotes system peaks. Peak labels denote assigned fatty acids
identiﬁed based on molecular mass and fragmentation patterns (see Supplemental 2
Fig. S-1 for exemplary mass spectra). C represents carbon; the ﬁrst value following C
denotes the number of carbons in the fatty acid alkyl chain and the last number represents
the number of unsaturated bonds. cyclo denotes a trimethylene cyclic structure. In
Trumenba, C16:1 and C17:cyclo are 9,10-hexadecenoic acid and 9,10-methylene
hexadecanoic acid, respectively. C18:1 and C19:cyclo are 11,12-octadecenoic acid and
11,12-methylene octadecanoic acid, respectively
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the resolved N-terminal lipopeptides are listed in Tables I and
II, alongside with the masses predicted from the known
amino acids and identiﬁed fatty acids via their picolinyl esters.
The relative mass errors between the predicted and the
observed mass values for all species were less than 5 ppm,
supporting the high conﬁdence in the lipid structure
identiﬁcation.
LC/MS of Intact NmB Lipoproteins and Characterization of
the N-Linked Fatty Acid
The full-length isoforms of the tri-acylated rLP2086-A05
and rLP2086-B01 lipoproteins can be resolved chromatograph-
ically using RP-UHPLC coupled to UHR MS. The proﬁles,
shown in Fig. 4, are similar to those of the N-terminal
lipopeptides resolved by the peptide mapping chromatography
method. The predicted mass value for a given lipid isoform is
based on the amino acid sequence and the N-terminal lipid
structure, both conﬁrmed by peptide mapping LC/MS and GC/
MS. The comparisons of the predicted and observedmass values
for all observed lipid isoforms for both lipoproteins are listed in
Tables III and IV, respectively. The relativemass errors between
the predicted and the observed mass values for all species were
less than 2 ppm. Greater than 97% of rLP2086-A05 and
rLP2086-B01 molecules are lipidated. Only low levels of
degradation products, with partial or no lipidation, were
detected.
Further characterization of the N-acylated fatty acids was
facilitated by de-O-acylation using a lipase that speciﬁcally
removes O-linked fatty acids. The lipase-treated rLP2086-
A05 and rLP2086-B01 were analyzed using the same RP-
UHPLC/UHR-ESI-QTOF MS method. The lipase digestion
Fig. 3. Lys-C peptide mapping for NmB rLP2086-A05 (a) and rLP2086-B01 (b).
Proteolytic peptides were resolved by RP-HPLC and detected using UV and UHR mass
spectrometry. Peak labels indicate peptide identiﬁcations based on accurate mass
determinations (i.e., agreement between the predicted and observed masses within
5 ppm). Peaks labeled as Lys-C represent autodigestion peptide products. Other minor
level peaks include deamidation (number symbol), pyro-glutamic acid formation (Pyro-Q),
and clipping (single and double asterisks). Insets are expanded views of the late-eluting
lipidated N-terminal peptides. The structures of the fatty acids in major peaks 1–3 and
trace to minor peaks A–E are listed in Tables I and II
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resulted in complete removal of the O-linked fatty acids of
rLP2086, as demonstrated by the degeneration of the
heterogeneous peaks in the 26- to 32-min region in Fig. 4 to
a single peak at 13–14 min (Supplemental 2 Fig. S-2). The
observed monoisotopic molecular masses of this single peak
for these proteins correspond to the masses predicted for the
respective polypeptide with an N-acylated C16:0 fatty acid on
the N-terminus of the thioglycerol-modiﬁed cysteine.
Secondary and Tertiary Structures
Atomistic Structural Models by NMR and Molecular Modeling
The NMR structure (16) for the non-lipidated NmB
fHbp (rP2086) subfamily B, a Cys1Met mutant (11), revealed
that the polypeptide folds into 18 β-strands and two short α-
helices, forming two distinct domains, the β-sheet N-terminal
domain and the β-barrel C-terminal domain. Each domain
contains a hydrophobic core formed with hydrophobic side
chains of the surrounding amino acids. The hydrophobic core
of each domain is protected by positively and negatively
charged residues forming large patches on the surface.
An atomic structure for rLP2086-A05 is not available in the
Protein Data Bank (PDB) (www.rcsb.org) so far. However, it is
expected that the overall higher-order structure of the subfamily
A and B proteins, rLP2086-A05 and rLP2086-B01, would be
similar since the two molecules share approximately 69%
sequence identity. This expectation of similar higher-order
structures is supported by the homology model of rLP2086-A05
built using the NMR structure of rLP2086-B01. Figure S-3 shows
the homology model of rLP2086-A05 (orange ribbons) super-
posed onto the NMR structure of rP2086-B01 (magenta ribbons).
Structural Characterization by Circular Dichroism and
Calorimetry
CD measures differential absorption of the left- and the
right-circularly polarized light due to the structural
Table I. Predicted and Observed Masses of NmB rLP2086-A05 N-Terminal Lys-C Peptide Containing Heterogeneous Lipid Isoforms
Peaka Fatty acid compositionb Predicted massc (Da) Observed massd (Da) Abundancee
A C16:0, C16:1, C14:0 3268.8858 3268.8868 Trace
A′ C16:0, C16:1, C16:1 3294.9014 3294.9024 Trace
B C16:0, C16:1, C15:0 3282.9014 3282.9007 Minor
B′ C16:0, C14:0, C16:0 3270.9014 3270.9018 Trace
1 C16:0, C16:1, C16:0 3296.9171 3296.9168 Major
C C16:0, C16:1, C18:1 3322.9327 3322.9322 Minor
2 C16:0, C17:cyclo, C16:0 3310.9327 3310.9318 Major
3 C16:0, C18:1, C16:0 3324.9484 3324.9461 Major
D C16:0, C18:1, C18:1 3350.9640 3350.9623 Minor
E C16:0, C19:cyclo, C16:0 3338.9640 3338.9610 Trace
aResolved and denoted in the inset of Fig. 3 (top panel)
bThe order of the fatty acid does not represent the positions of the fatty acids in the tri-acyl lipid moiety
cThe predicted masses (monoisotopic) for the lipopeptides were calculated based on the masses of the N-terminal 28 amino acids,
CGSSGGGGVAADIGTGLADALTAPLDHK, the S-glycerol linker, and the predicted fatty acids, in a structure as depicted in Fig. 1
dThe observed masses (monoisotopic) were derived from the mass spectra following de-isotoping with Extract software (Thermo Scientiﬁc)
eThe abundances were derived from the UV proﬁle
Table II. Predicted and Observed Masses of NmB rLP2086-B01 N-Terminal Lys-C Peptide Containing Heterogeneous Lipid Isoforms
Peaka Fatty acid compositionb Predicted massc (Da) Observed massd (Da) Abundancee
A C16:0, C16:1, C14:0 3614.0142 3614.0186 Trace
A’ C16:0, C16:1, C16:1 3640.0299 3640.0316 Trace
B C16:0, C16:1, C15:0 3628.0299 3628.0340 Minor
B’ C16:0, C14:0, C16:0 3616.0299 3616.0348 Trace
1 C16:0, C16:1, C16:0 3642.0455 3642.0470 Major
C C16:0, C16:1, C18:1 3668.0612 3668.0680 Minor
2 C16:0, C17:cyclo, C16:0 3656.0612 3656.0655 Major
3 C16:0, C18:1, C16:0 3670.0868 3670.0812 Major
D C16:0, C18:1, C18:1 3696.0925 3696.0970 Minor
E C16:0, C19:cyclo, C16:0 3684.0925 3684.0985 Trace
aResolved and denoted in the inset of Fig. 3 (bottom panel)
bThe order of the fatty acid does not represent the positions of the fatty acids in the tri-acyl lipid moiety
cThe predicted masses (monoisotopic) for the lipopeptides were calculated based on the masses of the N-terminal 33 amino acids,
CGSSGGGGSGGGGVTADIGTGLADALTAPLDHK, the S-glycerol linker, and the predicted fatty acids, in a structure as depicted in Fig. 1
dThe observed masses (monoisotopic) were derived from the mass spectra following de-isotoping with Extract software (Thermo Scientiﬁc)
eThe abundances were derived from the UV proﬁle
1567The Dual Role of the Lipids in Trumenba Vaccine
asymmetry of molecules. The far-UV CD spectrum for
proteins in the wavelength range of 195–250 nm is mostly
attributable to the amide bonds in polypeptide chains,
therefore reﬂecting the secondary structure in protein folding.
Fig. 4. RP-UHPLC proﬁles for intact NmB rLP2086-A05 (a) and rLP2086-B01 (b). Peaks between 26 and
32 min represent isoforms of each NmB rLP2086 lipoprotein due to the heterogeneous N-terminal lipid
compositions. The structures of the fatty acids in major peaks 1–3 and trace to minor peaks A–E are listed in
Tables III and IV. The trace level degradation products eluted around 12 min are mainly de-O-acylated species
Table III. Predicted and Observed Masses of NmB rLP2086-A05 Lipoprotein Containing Heterogeneous Lipid Isoforms
Peaka Fatty acid composition Predicted massc (Da) Observed massd (Da) Abundancee
N-linked O-linkedb
A C16:0 C16:1, C14:0 28,150.725 28,150.764 Trace
A’ C16:0 C16:1, C16:1 28,176.740 28,176.764 Trace
B C16:0 C16:1, C15:0 28,164.740 28,164.769 Minor
B’ C16:0 C14:0, C16:0 28,152.740 28,152.770 Trace
1 C16:0 C16:1, C16:0 28,178.756 28,178.774 Major
C C16:0 C16:1, C18:1 28,204.772 28,204.783 Minor
2 C16:0 C17:cyclo, C16:0 28,192.772 28,192.779 Major
3 C16:0 C18:1, C16:0 28,206.787 28,206.777 Major
D C16:0 C18:1, C18:1 28,232.803 28,232.810 Minor
E C16:0 C19:cyclo, C16:0 28,220.803 28,220.779 Trace
aResolved and denoted in the inset of Fig. 3 (top panel) and Fig. 4 (top panel)
bThe order does not represent the positions of the O-linked fatty acids
cThe predicted masses (monoisotopic) for the lipopeptides were calculated based on the masses of the amino acids in rLP2086-A05 sequence,
the S-glycerol linker, and the predicted fatty acid compositions
dThe observed masses (monoisotopic) were derived from the mass spectra following deconvolution of the charge envelope with maximum
entropy software and de-isotoping with SNAP software (Bruker Daltonics)
eThe abundances were derived from the UV proﬁle
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The near-UV CD spectrum for proteins in the wavelength
range from 250 to 350 nm is dominated by the absorbance of
aromatic amino acids (Trp and Tyr) and disulﬁde bonds. It is
sensitive to the tertiary folding and quaternary packing of
protein polypeptide chains.
As shown in Supplemental 2 Fig. S-4, the far-UV CD
spectra for the two proteins exhibit similar features, but are
not identical, possibly due to the differences in their amino
acid sequences. The near-UV CD spectra are also similar
after being normalized against the respective Tyr in each
molecule (the two molecules do not contain Trp and
disulﬁde bonds). All CD spectra in Fig. S-4 reﬂect well-
folded protein polypeptide chains under the conditions that
the antigens are known to self-associate and form micelle-
like complexes due to the hydrophobicity of the N-terminal
lipids (see BQuaternary Structure^ below).
DSC is commonly used to characterize thermally
induced unfolding of proteins by measuring heat capacity
as a function of temperature. Figure S-5 in Supplemental 2
shows the thermograms of rLP2086-A05 and rLP2086-B01.
Two distinct transitions were observed for rLP2086-B01,
whereas rLP2086-A05 exhibited one transition at a temper-
ature slightly higher than the second transition of rLP2086-
B01.
The thermal unfolding proﬁles of rLP2086-B01 were
previously studied using recombinant polypeptides that
correspond to the full-length and the C-terminal domain
of the non-lipidated rP2086-B01 (16). The thermogram for
the recombinant C-terminal domain is almost identical to
the second peak at 85°C in the thermogram for the full-
length molecule, suggesting that the second peak is due to
the unfolding of the C-terminal domain. Unlike the CD
spectra, which largely display the similarity between the
two lipoproteins in their secondary folding and tertiary
packing, the DSC proﬁles highlight that some aspect of the
higher-order structure is different between these two
lipoproteins.
Quaternary Structure
The size distributions of rLP2086 in non-denaturing
conditions, measured by size exclusion chromatography in-
line with multi-angle light scattering detectors (SEC-MALS),
are shown in Fig. 5a, b. The measured weight average molar
mass is ∼668,000 g/mol for rLP2086-A05 and ∼660,000 g/mol
for rLP2086-B01. Based on the monomeric molar masses of
both molecules being ∼28,000 g/mol, these measured average
masses suggest that fHbp lipoproteins associate into com-
plexes of approximately 24 mers.
The large complexes of rLP2086-A05 and rLP2086-
B01 are likely to exist as micelles. Both proteins contain
highly hydrophobic tri-acylated lipids at the N-termini and
high charge density on the surface of the folded polypep-
tide domains (16). They are, therefore, highly amphiphilic.
On the bacterial cell surface, the lipids anchor the
lipoproteins to bacterial cell walls by embedding in the
membrane bilayer. In the puriﬁed vaccine solutions, which
are free of membrane components, it is energetically
favorable for the lipids of multiple molecules to associate
with each other and form a hydrophobic core of a micelle,
with the hydrophilic polypeptide domains on the outer
layer to assemble (self-associate) in a side-by-side manner,
as illustrated in Fig. 5c.
To conﬁrm that the micellar structure is driven by the
association of the hydrophobic lipids, the size distribution
of the non-lipidated polypeptide of rP2086-B01 was ana-
lyzed using analytical ultracentrifugation sedimentation
velocity (AUC-SV), as shown in Supplemental 2 Fig. S-6.
The measured size was independent of the protein
concentration, with the peak sedimentation coefﬁcient
corresponding to the monomeric rP2086 molecule. This
result supports that the lipids of fHbp lipoproteins are
causing the formation of the micelles, and the micellar
state is the natural quaternary structure of the lipoproteins
in the vaccine formulation.
Table IV. Predicted and Observed Masses of NmB rLP2086-B01 Lipoprotein Containing Heterogeneous Lipid Isoforms
Peaka Fatty acid composition Predicted massc (Da) Observed massd (Da) Abundancee
N-linked O-linkedb
A C16:0 C16:1, C14:0 28,362.514 28,362.571 Trace
A’ C16:0 C16:1, C16:1 28,388.530 28,388.544 Trace
B C16:0 C16:1, C15:0 28,376.530 28,376.572 Minor
B’ C16:0 C14:0, C16:0 28,364.530 28,364.527 Trace
1 C16:0 C16:1, C16:0 28,390.546 28,390.588 Major
C C16:0 C16:1, C18:1 28,416.561 28,416.593 Minor
2 C16:0 C17:cyclo, C16:0 28,404.561 28,404.586 Major
3 C16:0 C18:1, C16:0 28,418.577 28,418.579 Major
D C16:0 C18:1, C18:1 28,444.592 28,444.584 Minor
E C16:0 C19:cyclo, C16:0 28,432.592 28,432.577 Trace
aResolved and denoted in the inset of Fig. 3 (bottom panel) and Fig. 4 (bottom panel)
bThe order does not represent the positions of the O-linked fatty acids
cThe predicted masses (monoisotopic) for the lipopeptides were calculated based on the masses of the amino acids in rLP2086-B01 sequence,
the S-glycerol linker, and the predicted fatty acid compositions
dThe observed masses (monoisotopic) were derived from the mass spectra following deconvolution of the charge envelope with maximum
entropy software and de-isotoping with SNAP software (Bruker Daltonics)
eThe abundances were derived from the UV proﬁle
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Chemical denaturation was performed to explore
possible roles of the protein polypeptide structure in micelle
formation. In the presence of 8 M urea in the SEC mobile
phase, the hydrodynamic size of rLP2086-A05 micelles
appears to be increased (Supplemental 2 Fig. S-7). This
result suggests, ﬁrstly, that the micelles were not dismantled
by the protein denaturant. The increase of the micellar size
upon the unfolding of the polypeptide domains can be due
to the more extended and ﬂexible polypeptide chains of
each molecule in the micelles, which may increase the
effective hydrodynamic radius. Secondly, as the polypeptide
domains become less bulky and rigid, space is made
available for more molecules, leading to the increased
average mass of the micelles.
The above results indicate that the optimal number of
molecules per micelle is determined by the length of the lipid
moiety relative to the size/volume of the polypeptide
domain, with longer lipids being in favor of larger micelles
and larger or bulkier polypeptide domains being in favor of
smaller micelles by limiting the number of molecules in a
micelle. This implies that the size range of micelles formed
by a given lipoprotein should not be concentration-
dependent at concentrations above the critical micellar
concentration (CMC). The SEC proﬁles shown in Fig. 5a, b
are largely independent of the loading concentration when
greater than 0.2 mg/mL (∼7 μM). Below CMC, micelles are
in concentration-dependent dynamic equilibria with non-
associated monomers. AUC-SV was used to study the size
distribution below 0.2 mg/mL. Figure 5d shows the c(s)
proﬁles for rLP2086-B01 solutions from 3.5 μM (∼0.1 mg/
mL) to 10 μM (∼0.28 mg/mL). At 3.5 μM, the average size
was approaching that of non-lipidated molecules (see
Supplemental 2 Fig. S-6), while at concentrations above
8 μM, the average size reached a maximum. Therefore, the
estimated CMC for rLP2086 is ∼0.2 mg/mL (∼7 μM, or
∼0.02% w/v) at 20°C. No surfactant other than Zwittergent
3–10 at a low level (0.1%, lower than the CMC) was present
in the solution.
The formulation of Trumenba contains low level of
polysorbate 80 (PS-80), which is commonly used to increase
the stability of biologics. The micelle-prone lipoproteins and
surfactant molecules constitute a binary micellar system.
The characterization of such a system consisting of rLP2086
and PS-80 is described in Supplemental 1.
Fig. 5. SEC-MALS measurements for NmB rLP2086-A05 (a) and rLP2086-B01 (b). The chromatograms
by UV detector (blue lines) are superimposed with the molar mass values (red circles) obtained by MALS
detector in-line with the UV detector. c Schematic model of micelles in NmB rLP2086 lipoprotein vaccines.
The bulky and charged polypeptide chains and the elongated and hydrophobic lipid moiety form the outer
layer and the core of the micelles, respectively. The tertiary structure of the polypeptide chain is based on
the NMR structure for NmB rLP2086-B01. d Sedimentation coefﬁcient distributions by AUC for NmB
rLP2086-B01 at 3.6 μM (purple line and dot), 5.5 μM (red line and circle), 8 μM (black line and diamond),
and 10 μM (green line and triangle) in PBS with 0.1% Zwittergent 3–10
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Functional Role of the N-Terminal Lipids
Interactions of NmB Lipoproteins with hTLR2-Expressing
Cells
The immune-enhancing effect of the N-terminal lipids
of rLP2086s was demonstrated previously by comparing the
results of the lipidated and non-lipidated recombinant fHbp
molecules in the serum bactericidal antibody assay, which
measures the capability of the antibodies in the sera of
immunized mice to kill target meningococcal strains in a
complement-dependent fashion (11,19). The mechanism for
the immune-enhancing effect studied with other bacterial
lipopeptides and lipoproteins suggests lipoprotein recogni-
tion of TLR receptors on cells of the innate immune system
(20–23). In this study, the interactions of rLP2086 with
TLR2 and/or TLR2/TLR1 complexes on cell surfaces, and
the subsequent cell activation, were conﬁrmed using
HEK293 hTLR2 cells that express human TLR2 and
TLR1. Upon TLR2 activation, the cells express secreted
embryonic alkaline phosphatase (SEAP), which can be
quantitated. In this assay, the tri-acylated lipopeptide
Pam3CSK4, which is a standard TLR2/TLR1 agonist, and
PBS were used as the positive and negative controls,
respectively. The Trumenba sample, containing equal
amounts of rLP2086-A05 and rLP2086-B01 lipoproteins,
stimulated HEK293 hTLR2 cells in a dose-dependent
manner similar to the activity observed with Pam3CSK4
(Fig. 6a).
Critical Role of TLR2 in Cell Activation by NmB Lipoproteins
The central role of TLR2 in the activation of HEK293
hTLR2 cells by Trumenba antigens was further conﬁrmed by
inhibiting cell activation with a neutralizing anti-TLR2
antibody. The cells were incubated with anti-TLR2 monoclo-
nal antibody (mAb) at various concentrations prior to the
stimulation by Pam3CSK4 or the NmB rLP2086 components
at ﬁxed concentrations. The cell activations by both agonists
increased as anti-TLR2 mAb decreased (Fig. 6b), suggesting
that the cellular responses to the agonists require speciﬁc
interactions of these agonists with TLR2 on the cell surface.
Critical Role of the O-Linked Fatty Acids in the Activation of
TLR2-Expressing Cells
The critical role of the O-linked fatty acids was further
demonstrated by comparing the activation of HEK-Blue
hTLR2 cells induced by the intact and the lipase-treated
rLP2086-A05, as shown in Fig. 6c. Lipase treatment resulted
in the removal of the two O-linked fatty acids, giving rise to
the mono-N-acyl NmB rLP2086-A05, or de-O-acylated NmB
rLP2086-A05. The puriﬁed material contained full-length
protein polypeptide and the N-linked fatty acid, predomi-
nantly C16:0 (Supplemental 2 Fig. S-2 and Tables III and IV).
Lipopeptide Pam3CSK4 was also used as a comparator. At
similar molar concentrations, the intact NmB rLP2086-A05
exhibited a high cell activation activity close to that of
Pam3CSK4, while the lipase-treated mono-N-acyl NmB
rLP2086-A05 exhibited signiﬁcantly attenuated activity.
Fig. 6. a Activation of HEK293 hTLR2 cells by Pam3CSK4 standard
(solid gray square) and Trumenba vaccine (solid black triangle)
containing equal amounts of NmB rLP208-A05 and rLP2086-B01
lipoproteins. PBS solution (thatched circle) was used as the negative
control. Each data point represents the average of duplicate tests. b
Effect of anti-TLR2 mAb on the activation of HEK293 hTLR2 cells
induced by PAM3CSK4 (0.67 nM, solid gray square) and Trumenba
vaccine (0.08 nM, solid black triangle) containing equal amounts of
NmB rLP208-A05 and rLP2086-B01. PBS solution (thatched circle)
was used as the negative control. Each data point represents the
average of duplicate tests. c Activation of HEK293 hTLR2 cells by
Pam3CSK4 (solid gray), NmB rLP2086-A05 (zigzag), and mono-N-
acyl rLP2086-A05 (solid black). PBS solution (thatched) was used as
the negative control. The activities of the lipopeptide and lipoprotein
samples were compared at a ﬁxed concentration of 0.66 nM in the
assay. Bar graphs represent the mean and error bars represent the
standard deviation of N = 14 replicates. The Y-axis for all panels is in
absorbance units at the indicated wavelengths
1571The Dual Role of the Lipids in Trumenba Vaccine
Taken together, the results described above support the
perspective that the presence of the O-linked fatty acids in
the tri-acylated NmB rLP2086 lipoproteins is critical for the
stimulation of TLR2/TLR1-expressing cells and, thus, explain
the immune enhancement observed with the lipidated forms
of fHbps compared to their non-lipidated forms.
DISCUSSION
The Polypeptide and Lipid Domains of Trumenba Lipoproteins
Play Distinct Structural Roles
The Polypeptide Domain of rLP2086
The atomic structure of NmB rLP2086-B01 polypeptide
by NMR in the solution phase was consistent with the X-ray
crystal structures reported for similar NmB lipoproteins
(24,25). Both showed that the polypeptides of the lipopro-
teins fold into mainly two conformational motifs in two side-
by-side domains, i.e., the N-terminal and the C-terminal
domains. This domain structure was shown to be important
for factor H binding to fHbps (24), which allows meningo-
coccal bacteria to avoid the human innate immune system.
The human factor H (hfH) in the crystal structure is shown to
simultaneously interact with both the N-terminal and the C-
terminal domains. The atomic structure for NmB rLP2086-
A05 has not been resolved. Given the fact that the two fHbp
subfamilies share similar hfH binding property, it is likely that
the conformations of the hfH binding sites in the two
subfamilies are similar. The hfH binding sites contain large
numbers of subfamily-deﬁning residues (25,26). The regions
that are largely composed of conserved residues are expected
to be also similar. This is supported by the superimposed
crystal structures of a v3 variant (corresponds to one branch
of subfamily A (14)) with a v1 variant (corresponds to
subfamily B (14)) (25) and by the homology model built for
rLP2086-A05 using the NMR structure of rLP2086-B01
(Supplemental 2 Fig. S-3). The far-UV and near-UV CD
spectra, which reﬂect the secondary folding and tertiary
packing of protein polypeptides, respectively, of NmB
rLP2086-A05 and rLP2086-B01 are similar to each other at
all wavelengths (Supplemental 2 Fig. S-4). This indicates that,
in the solution phase, the overall structural features of the
two molecules in the native state are similar.
The Lipid Motif of rLP2086
One of the novel ﬁndings in this work is the micellar
quaternary structure of NmB rLP2086-A05 and rLP2086-B01
lipoproteins, as well as the binary micellar systems in the
presence of surfactant molecules, via size distribution analy-
ses using AUC and SEC-MALS. Structurally modiﬁed
materials, such as non-lipidated proteins, were used to
demonstrate the role of the lipids in the formation of
lipoprotein micelles (Supplemental 2 Fig. S-6). A denaturing
condition for proteins was applied to examine the impact of
the spatial dimensions of the polypeptide domain on the size
distribution of the lipoprotein micelles (Supplemental 2
Fig. S-7). It was concluded that the hydrophobicity of the
lipid moiety in the lipoproteins drives the self-association of
the puriﬁed lipoproteins to form micelles. This is similar to
the role of anchoring the lipoproteins to the bacterial cell
walls by embedding themselves in the lipid bilayer membrane
(16). The average size of the micelles is determined by the
optimal number of lipoproteins that ﬁt in individual micelles.
This is, in turn, determined by the relative dimensions of the
lipids and the polypeptide region. Under the conditions used
in the SEC-MALS studies (Fig. 5a, b), this number is on
average ∼24 for puriﬁed Trumenba components. Signiﬁcant
changes in the structure of the lipids or conformation of the
protein polypeptides can induce changes in the size distribu-
tion of the micelles.
Immune-Enhancing Effects of the N-Terminal Lipids of rLP2086
During the design of Trumenba, it was noted in
preclinical in vivo studies that the lipidated forms of fHbps
were more immunogenic compared to the non-lipidated
forms; thus, the lipidated forms were chosen as vaccine
antigens (11). To fully elucidate the lipid structures of the
Trumenba antigens and to understand the immune-enhancing
mechanism, the lipidated structures were thoroughly charac-
terized by chromatographic techniques and mass spectrome-
try. Data shown in Figs. 3 and 4, for the N-terminal peptides
and the intact molecules, respectively, demonstrated that
>97% of rLP2086-A05 and rLP2086-B01 are lipidated, and
all lipid isoforms are tri-acylated with fatty acids of 14 carbons
or longer (Tables I, II, III, and IV), in agreement with fatty
acids detected by GC/MS. The characterization data for
Trumenba reported in this work are consistent with data in
the literature for other E. coli-produced lipoproteins, e.g.,
rAg473 (27).
When associated with the bacteria, the lipids of the
bacterial lipoproteins play mainly a structural role of anchor-
ing the lipoproteins to bacterial cell walls. However, during
infection, the fHbp lipoproteins can dissociate from the
bacteria and the exposed lipid moiety can play different roles
in the disease-causing infection. It was discovered in the late
1980s that conjugation of Pam3CSS (tripalmitoyl Cys-Ser-
Ser) or Pam2CSS (di-O-acylated palmitoyl Cys-Ser-Ser) to
peptides derived from bacterial or viral proteins could
convert the immunologically inactive peptides into potent
vaccines that provided long-lasting protection against bacte-
rial or viral infections in animal models. This effect was
enabled by induction of neutralizing antibodies (28,29) and by
in vivo priming of epitope-speciﬁc cytotoxic T cells and
memory T cells (30–32). Since antibodies to the lipid moieties
are not generated in vivo, the immune-enhancing effect of the
lipids is believed to be similar to that of a conventional
adjuvant, and thus, bacterial lipoprotein/lipopeptide-
containing vaccines are recognized as one category of self-
adjuvanting vaccines (21–23,33). Other categories include
lipid-core peptides, single-chain palmitoylated peptides, and
glycolipid analogues of bacterial lipopolysaccharides (21).
Complete understanding of the mechanism for the
adjuvanting activity of various lipids attached to polypeptide
immunogens is still evolving. It was perceived in early days
that the lipids simply anchor the lipoproteins/lipopeptides to
the surface membrane of immune cells to facilitate the
internalization. Recent research suggested that the lipid
moieties interact with various TLRs, a type of membrane-
bound pattern recognition receptors (PRRs), to drive the
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endocytosis of the lipoproteins by antigen-presenting cells
(34) and induce various immune responses (21,22,32). PRR is
a key component of the innate immune system to identify
pathogen-associated molecular patterns (PAMPs) (35).
More than ten human TLRs have been identiﬁed so far
that are involved in recognizing different PAMPs. TLR2 is
essential in the recognition of bacterial lipoproteins/
lipopeptides (20,36). TLR2 in combination with other TLRs
determine the speciﬁcity for lipid structures. Crystal struc-
tures of the TLR2–TLR1 complex interacting with a tri-
acylated lipopeptide, Pam3CSK4, and the TLR2–TLR6
complex interacting with a di-O-acylated lipopeptide,
Pam2CSK4, were solved (37). The two O-linked fatty acids
in both structures are shown to be in parallel in the lipid-
binding channel of TLR2, while the N-linked fatty acid of
Pam3CSK4 is in the lipid-binding channel of TLR1. It was
suggested that the simultaneous interactions of the tri-
acylated lipid with the ectodomains of TLR2 and TLR1, or
the di-acylated lipids with TLR2 and TLR6, bring the C-
terminal intracellular domains of these receptors into a closer
contact (36).
In human blood, TLR2 has the highest expression on
CD14+ monocytes (38), which mature and differentiate into
phagocytes such as dendritic cells (DC) and macrophages
when migrating to tissues. In DC, the dimerization of the
intracellular domains of TLR2 and TLR1 or TLR6 triggers a
cascade of intracellular signal transductions and kinase
activations that result in the de-inhibition of NFkB, a nuclear
factor that controls the transcription of DNA. The free NFkB
can translocate to the nucleus, where it binds to the enhancer
or promoter regions of target genes and regulates their
transcription (22). The target genes of NFkB control all the
functions associated with DC maturation, and thus the chain
of events leading to the priming of the immune responses,
which likely include (1) activation of antigen-speciﬁc CD4+ T
cells that can secrete cytokines and induce B cells to produce
antigen-speciﬁc antibodies against the internalized, processed,
and presented peptide epitopes; (2) activation of cytotoxic
CD8+ T cell that can lyse infected cells and differentiate to
long-lived memory T cells; and (3) secretion of cytokines that
activate other immune cells, e.g., NK cells and phagocytes, to
attack the infected cells (22). The killing of pathogens and
infected cells by cytotoxic T cells and NK cells can also be
induced by direct interactions of bacterial lipoproteins with
TLR2 on the surface of these immune cells in the absence of
TLR1 (39,40). However, only the activated B cells can
produce functional antibodies and can differentiate to mem-
ory B cells that produce antigen-speciﬁc antibodies upon
future invasion of the same bacteria, therefore eliminating
these bacteria more rapidly. By this mechanism, the epitope-
containing polypeptide domain of the lipoproteins functions
as the antigen, with the attached lipids functioning as
adjuvants that prime the immune system for stronger
responses to the antigens. Together, they constitute self-
adjuvanting vaccines.
The two lipoproteins in Trumenba, rLP2086-A05 and
rLP2086-B01, which contain identical lipid isoforms (Tables I,
II, III, and IV), exhibited characteristics of the above-
described self-adjuvanting vaccines and, as shown previously,
were required for enhanced immune responses compared to
the non-lipidated forms (11). Further, the de-O-acylated
molecules were shown in this work to be inactive by an
in vitro assay using hTLR2-expressing HEK293 cells (Fig. 6c).
The critical role of TLR2 in cell stimulation by Trumenba was
shown by speciﬁc blocking of TLR2 with anti-TLR2 antibod-
ies (Fig. 6b). These results are consistent with the reports that
the O-linked fatty acids only interact with TLR2 (36) and that
TLR2 is critical in the activation of the immune system by
bacterial lipoproteins (22). We therefore conclude that the
Trumenba antigens constitute a self-adjuvanting vaccine, with
the protein polypeptides giving rise to functional bactericidal
antibodies, and the N-terminal lipids serving as an adjuvant,
capable of activating the innate immune system via the
recognition by TLR2 and promoting its crosstalk with the
adaptive immune system to produce antibodies against the
polypeptide epitopes.
However, the critical role of the lipids in interacting with
TLR2 appears to conﬂict with the role of the lipids in
lipoprotein micelles in the Trumenba formulation, which also
increase the stability of the puriﬁed lipoprotein molecules.
The former requires the lipid moiety to be fully accessible,
while the latter results in the burial of the lipids in the
hydrophobic core of the micelles. If the lipid moiety remains
buried in the micelles following vaccination, the interactions
with TLRs may be less effective, hence a lower immune-
enhancing effect. To achieve both the desired stability before
vaccination and a high immunogenic efﬁcacy after vaccina-
tion, the lipoproteins need to form micelles in the formulation
and then dissociate upon administration. This requires
formulating the lipoproteins at concentrations slightly above
the CMC of the lipoprotein micelles, which is estimated for
NmB rLP2086 lipoproteins to be ∼0.2 mg/mL. Each dose of
Trumenba contains a total of 0.12 mg lipoproteins (0.06 mg
rLP2086-A05 and 0.06 mg rLP2086-B01) formulated in
0.5 mL solution, resulting in a total concentration of
0.24 mg/mL. When the vaccine diffuses following the
administration and reaches in vivo concentrations below
0.2 mg/mL, the micelles will disperse, exposing the lipid
moiety of individual lipoproteins to interact with their target
TLRs.
All Lipid Isoforms in TrumenbaAre Effective Adjuvants—Effects
of Lipid Structures on TLR2-Dependent Stimulation of Immune
Responses
The crystal structures of the TLR2–TLR1 complex
interacting with tri-acylated lipids, and of the TLR2–TLR6
complex interacting with di-O-acylated lipids, provided struc-
tural basis for the speciﬁcity of surface receptors of the innate
immune cells in recognizing lipidated bacterial components,
but are not sufﬁcient to determine the impact of ﬁner
structures of the fatty acids in the lipids on the potency to
stimulate immune responses. Extensive experimental studies
were conducted to address these gaps for the purpose of
developing more potent lipopeptide vaccines, taking advan-
tage of modern technologies to synthesize lipopeptides and
the stable cell lines that express desired human receptors.
Synthetic tri-acyl-CSSNASK4 lipopeptides with the N-
linked fatty acids being all Pam (C16:0) and the two O-linked
fatty acids varying from C6 to C20, some containing
unsaturated bonds (Ole and Lin are both C18, Ole contains
one unsaturated bond (C18:1), and Lin contains two
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unsaturated bonds (C18:2)), were studied using HEK293
hTLR2 cell lines (41). The results by monitoring IL-8
secretion and NFkB activation showed similar dependence
of cell activation on structures of the O-linked fatty acids.
Both assays observed baseline-level activities, with the carbon
chains of the O-linked fatty acids ranging from C6 to C10.
There were then sharp increases in the activity with the O-
linked fatty acids from C10 to C14. From C14 to C20, IL-8
secretion was more or less plateaued, whereas NFkB
activation continued to increase.
Other factors, including the length of the N-linked fatty
acids, were also investigated in the above-mentioned work.
The observed structural requirements for tri-acylated
lipopeptides to exhibit full immune activation activity are:
(1) The minimum length of the two O-linked fatty acids is
C14; (2) lipids with both O-linked fatty acids from C14 to C20
exhibit similar activities; (3) the minimum length of the N-
linked fatty acid for full activity is C6; (4) lipids with the N-
linked fatty acids from C6 to C18 exhibit similar activities;
and (5) the O-linked fatty acids ≥C14 with one or two
unsaturated bonds exhibit similar activities to the correspond-
ing saturated fatty acids.
The two recombinant bacterial lipoproteins in
Trumenba, rLP2086-A05 and rLP2086-B01, exhibit heteroge-
neities that are resolvable by RP-HPLC (Fig. 4). The
components under the peaks eluted between 26 and 32 min
have been identiﬁed by chromatographic and mass spectrom-
etry techniques to be lipid variants (Tables I, II, III, and IV).
Within each subfamily, no major difference in polypeptide
chain was observed; all differences in mass were due to the
heterogeneity in the lipid structure. The two lipoproteins
contained the same lipid variants with similar distributions.
Further, the lipid variants, which were predominantly tri-
acylated, contained the same N-linked fatty acid, Pam
(C16:0), as well as the two O-linked fatty acids, which
differentiate the lipid variants via combinations of fatty acids
of lengths ranging from C14 to C19, with saturated, unsatu-
rated, and cyclic structures. The key ﬁnding is that all the lipid
isoforms in each subfamily meet the above-described struc-
tural requirements, i.e., fatty acids ≥C14, for full immune
stimulation activity. Therefore, all lipidated molecules in
Trumenba should have similar self-adjuvanting activities.
CONCLUSIONS
Trumenba is a well-characterized vaccine composed of
two recombinant bacterial lipoproteins, NmB rLP2086-A05
and rLP2086-B01, which are tri-acylated with fatty acids of
14–19 carbon atoms in length. Both lipoproteins self-associate
and exhibit a micelle-like quaternary structure due to the
hydrophobicity of the N-terminal lipids, which enhances
stability of the product (CMC∼0.2 mg/mL or ∼7 μM). The
N-terminal lipid motif was previously indicated to be critical
to the immune enhancement (11). It is demonstrated in this
work that the lipids interact with the TLR2/TLR1 complex,
which stimulates cell activation. Further, the two O-linked
fatty acids are responsible for all the activation effect via their
exclusive interactions with TLR2. It is, therefore, concluded
that Trumenba is a self-adjuvanting vaccine, with the lipid
motif of the lipoprotein components playing the role of
adjuvant. It is the ﬁrst example of a licensed vaccine that has
a documented adjuvant activity incorporated into its target
antigens. One of the novelties of Trumenba is the dual role of
the N-terminal lipids in stabilizing the higher-order structure
of rLP2086 and in the self-adjuvanticity of the vaccine.
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